Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19

In an observational study, researchers report that the combination of casirivimab and imdevimab -- two monoclonal antibody treatments under Food and Drug Administration emergency use authorization -- keep high-risk patients out of the hospital when infected with mild to moderate COVID-19.

from Top Health News -- ScienceDaily https://ift.tt/3gILcnA